219 related articles for article (PubMed ID: 23479398)
1. Prediction of drug-drug interactions between various antidepressants and efavirenz or boosted protease inhibitors using a physiologically based pharmacokinetic modelling approach.
Siccardi M; Marzolini C; Seden K; Almond L; Kirov A; Khoo S; Owen A; Back D
Clin Pharmacokinet; 2013 Jul; 52(7):583-92. PubMed ID: 23479398
[TBL] [Abstract][Full Text] [Related]
2. Assessment of pharmacokinetic interactions of the HCV NS5A replication complex inhibitor daclatasvir with antiretroviral agents: ritonavir-boosted atazanavir, efavirenz and tenofovir.
Bifano M; Hwang C; Oosterhuis B; Hartstra J; Grasela D; Tiessen R; Velinova-Donga M; Kandoussi H; Sevinsky H; Bertz R
Antivir Ther; 2013; 18(7):931-40. PubMed ID: 23963204
[TBL] [Abstract][Full Text] [Related]
3. The relation between treatment outcome and efavirenz, atazanavir or lopinavir exposure in the NORTHIV trial of treatment-naïve HIV-1 infected patients.
Josephson F; Andersson MC; Flamholc L; Gisslén M; Hagberg L; Ormaasen V; Sönnerborg A; Vesterbacka J; Böttiger Y
Eur J Clin Pharmacol; 2010 Apr; 66(4):349-57. PubMed ID: 19967342
[TBL] [Abstract][Full Text] [Related]
4. Clinical pharmacokinetics and summary of efficacy and tolerability of atazanavir.
Le Tiec C; Barrail A; Goujard C; Taburet AM
Clin Pharmacokinet; 2005; 44(10):1035-50. PubMed ID: 16176117
[TBL] [Abstract][Full Text] [Related]
5. Clinical assessment of potential drug interactions of faldaprevir, a hepatitis C virus protease inhibitor, with darunavir/ritonavir, efavirenz, and tenofovir.
Sabo JP; Kort J; Ballow C; Haschke M; Battegay M; Fuhr R; Girlich B; Schobelock M; Feifel U; Lang B; Li Y; Elgadi M
Clin Infect Dis; 2014 Nov; 59(10):1420-8. PubMed ID: 25091302
[TBL] [Abstract][Full Text] [Related]
6. Use of in vitro to in vivo extrapolation to predict the optimal strategy for patients switching from efavirenz to maraviroc or nevirapine.
Schipani A; Back D; Owen A; Davies G; Khoo S; Siccardi M
Clin Pharmacokinet; 2015 Jan; 54(1):107-16. PubMed ID: 25245943
[TBL] [Abstract][Full Text] [Related]
7. Interaction of disulfiram with antiretroviral medications: efavirenz increases while atazanavir decreases disulfiram effect on enzymes of alcohol metabolism.
McCance-Katz EF; Gruber VA; Beatty G; Lum P; Ma Q; DiFrancesco R; Hochreiter J; Wallace PK; Faiman MD; Morse GD
Am J Addict; 2014; 23(2):137-44. PubMed ID: 24118434
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of darunavir at 900 milligrams and ritonavir at 100 milligrams once daily when coadministered with efavirenz at 600 milligrams once daily in healthy volunteers.
Soon GH; Shen P; Yong EL; Pham P; Flexner C; Lee L
Antimicrob Agents Chemother; 2010 Jul; 54(7):2775-80. PubMed ID: 20385850
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics of once-daily darunavir-ritonavir and atazanavir-ritonavir over 72 hours following drug cessation.
Boffito M; Jackson A; Amara A; Back D; Khoo S; Higgs C; Seymour N; Gazzard B; Moyle G
Antimicrob Agents Chemother; 2011 Sep; 55(9):4218-23. PubMed ID: 21709075
[TBL] [Abstract][Full Text] [Related]
10. Interactions between alcohol and the antiretroviral medications ritonavir or efavirenz.
McCance-Katz EF; Gruber VA; Beatty G; Lum PJ; Rainey PM
J Addict Med; 2013; 7(4):264-70. PubMed ID: 23666322
[TBL] [Abstract][Full Text] [Related]
11. Physiologically Based Pharmacokinetic Modeling to Predict Drug-Drug Interactions with Efavirenz Involving Simultaneous Inducing and Inhibitory Effects on Cytochromes.
Marzolini C; Rajoli R; Battegay M; Elzi L; Back D; Siccardi M
Clin Pharmacokinet; 2017 Apr; 56(4):409-420. PubMed ID: 27599706
[TBL] [Abstract][Full Text] [Related]
12. Cobicistat: a review of its use as a pharmacokinetic enhancer of atazanavir and darunavir in patients with HIV-1 infection.
Deeks ED
Drugs; 2014 Feb; 74(2):195-206. PubMed ID: 24343782
[TBL] [Abstract][Full Text] [Related]
13. Effect of efavirenz, nevirapine, etravirine, and raltegravir administration on the pharmacokinetics of ritonavir-boosted darunavir in a population of HIV-infected patients.
Dailly E; Allavena C; Bouquié R; Deslandes G; Raffi F; Jolliet P
AIDS Res Hum Retroviruses; 2013 Jan; 29(1):42-6. PubMed ID: 23148588
[TBL] [Abstract][Full Text] [Related]
14. Effects of ritonavir-boosted darunavir vs. ritonavir-boosted atazanavir on lipid and glucose parameters in HIV-negative, healthy volunteers.
Tomaka F; Lefebvre E; Sekar V; Van Baelen B; Vangeneugden T; Vandevoorde A; Diego Miralles G
HIV Med; 2009 May; 10(5):318-27. PubMed ID: 19210693
[TBL] [Abstract][Full Text] [Related]
15. Preclinical assessment of the interactions between the antiretroviral drugs, ritonavir and efavirenz, and the tyrosine kinase inhibitor erlotinib.
Deeken JF; Beumer JH; Anders NM; Wanjiku T; Rusnak M; Rudek MA
Cancer Chemother Pharmacol; 2015 Oct; 76(4):813-9. PubMed ID: 26330331
[TBL] [Abstract][Full Text] [Related]
16. Antiretroviral drug exposure in the female genital tract: implications for oral pre- and post-exposure prophylaxis.
Dumond JB; Yeh RF; Patterson KB; Corbett AH; Jung BH; Rezk NL; Bridges AS; Stewart PW; Cohen MS; Kashuba AD
AIDS; 2007 Sep; 21(14):1899-907. PubMed ID: 17721097
[TBL] [Abstract][Full Text] [Related]
17. CYP3A induction and inhibition by different antiretroviral regimens reflected by changes in plasma 4beta-hydroxycholesterol levels.
Josephson F; Bertilsson L; Böttiger Y; Flamholc L; Gisslén M; Ormaasen V; Sönnerborg A; Diczfalusy U
Eur J Clin Pharmacol; 2008 Aug; 64(8):775-81. PubMed ID: 18458892
[TBL] [Abstract][Full Text] [Related]
18. Influence of tenofovir, nevirapine and efavirenz on ritonavir-boosted atazanavir pharmacokinetics in HIV-infected patients.
Dailly E; Tribut O; Tattevin P; Arvieux C; Perré P; Raffi F; Jolliet P
Eur J Clin Pharmacol; 2006 Jul; 62(7):523-6. PubMed ID: 16763827
[TBL] [Abstract][Full Text] [Related]
19. Steady-state pharmacokinetics of tenofovir-based regimens in HIV-infected pediatric patients.
King JR; Yogev R; Jean-Philippe P; Graham B; Wiznia A; Britto P; Carey V; Hazra R; Acosta EP;
Antimicrob Agents Chemother; 2011 Sep; 55(9):4290-4. PubMed ID: 21670182
[TBL] [Abstract][Full Text] [Related]
20. In silico prediction of efavirenz and rifampicin drug-drug interaction considering weight and CYP2B6 phenotype.
Rekić D; Röshammar D; Mukonzo J; Ashton M
Br J Clin Pharmacol; 2011 Apr; 71(4):536-43. PubMed ID: 21395646
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
